Примери за използване на Prolactinoma на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Prolactinoma and Pregnancy: What Is the Risk?
Causes of the disease and its types 2. Symptoms of prolactinoma 3.
Key words: prolactinoma, treatment, dopamine agonists.
The hormone-active tumor of the anterior lobe of the pituitary gland is prolactinoma.
Prolactinoma is diagnosed using computed tomography.
Some blood tests are generally done to exclude underlying disease,such as Hypogonadism and prolactinoma.
Prolactinoma and hyperprolactinemia are not life-threatening.
They are also used to treat conditions including hyperprolactinaemia and prolactinoma, and to prevent lactation and migraine.
Prolactinoma of the pituitary gland in women, with pregnancy and men.
You need to know that the frequency of prolactinoma relapses in patients, within 6 years after surgery, is 50%.
Summary: Prolactinoma is the most frequent benign and hormone-secreting tumor of the pituitary gland occuring in women and men.
Causes of the disease and its types 2. Symptoms of prolactinoma 3. Diagnosis and treatment of prolactinomas pro….
Veralipride treatment is contra-indicated in patients with prolactindependent tumours such as pituitary gland prolactinoma and breast cancer.
A pituitary tumor- prolactinoma, which produces an excessive amount of the hormone;
Because elevated prolactin can disrupt the reproductive system(hypogonadism),some of the signs and symptoms of prolactinoma are specific to females or males.
Left untreated, a prolactinoma may grow large enough to compress your optic nerve.
Because elevated levels of prolactin cause disruption of the reproductive system,some of the signs and symptoms of Prolactinoma are specific to females or males.
Doctors can often treat prolactinoma with medications to restore your prolactin level to normal.
In vivo and in vitro experiments on pituitary of Wistar rats demonstrated that 17-beta-estradiol activates the proliferation of lactotropic cells andcause development of prolactinoma.
Prolactinoma is a neoplasm of the anterior lobe of the pituitary gland, which has all the signs of good quality and actively secreting prolactin.
Therapy with medications not only normalizes the level of PRL, but also reduces the size of the tumor(prolactinomas), andwith long-term treatment, in some cases, the prolactinoma completely disappears.
Symptoms of prolactinoma are caused by hyperprolactinemia- too much prolactin in the blood- or by pressure of the tumor on surrounding tissues.
It is not recommended for use in people withallergic reactions to the components of the drug, bleeding from the digestive tract,intestinal obstruction, prolactinoma, during lactation, up to 5 years of age or weighing up to 20 kilograms.
A woman with a prolactinoma should discuss her plans to conceive with her physician so she can be carefully evaluated prior to pregnancy.
The CHMP considered the MAH responses and agreed that although data may suggest that prolactin is involved in breast cancer etiology, further studies are required to establish a formal link, and therefore adopted the following wording, addressing the potential risks of hyperprolactinaemia,although without specific inclusion of prolactinoma and breast cancer.
A woman with a prolactinoma should discuss her plans to conceive with her physician so that she can be carefully evaluated prior to becoming pregnant.
The CHMP considered the MAH responses and agreed that although data may suggest that prolactin is involved in breast cancer etiology, further studies are required to establish a formal link, and therefore adopted the following wording, addressing the potential risks of hyperprolactinaemia,although without specific inclusion of prolactinoma and breast cancer.
When prolactinoma occurs in males and females, there are significant distinctive features of clinical symptoms, in connection with which oncologists Read the full entry».
For section 4.4, the CHMP implemented a revised wording for the hyperprolactinaemia section,excluding specific mention of prolactinoma and breast cancer, as although data supporting a possible relationship between hyperprolactinaemia and risk of some prolactin-dependent tumours exists, the data is still largely inconclusive from a clinical perspective.
Recommendations of medical breast monitoring and intermittent schedule(20 days followed by a 10day period of non-treatment) to reduce the risk of hyperprolactinemia, aimed to improve the breast safety(however, it is unknown whether this measure has any effect on the observed adverse event pattern related to hyperprolactinemia like breast enlargement, galactorrhoea andrisk for patients with prolactin-dependent tumours such as pituitary gland prolactinoma and breast cancer).